Medicamen Biotech Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32

Medicamen Biotech has filed its quarterly and yearly statement under SEBI Regulation 32 for fund utilization. The company raised Rs. 53.57 crore via a preferential issue on 24 April 2025. As of 31 March 2026, Rs. 29.30 crore has been utilized out of the total raised. The funds were allocated across six stated objects: development of 50 drug SKUs for regulated markets, registration of dossiers, enhanced working capital, facility upgrades, domestic market expansion, and general corporate purposes. The Audit Committee reviewed the statement on 27 May 2026 and confirmed there is no deviation or variation in the utilization of funds. No shareholder approval was needed as there were no changes to the originally stated objects.